O'Reilly EM, et al. - Veliparib combined with cisplatin and gemcitabine was evaluated for the safety, dose-limiting toxicities (DLTs), maximum tolerated dose, and recommended phase 2 dose (RP2D). In addition, researchers determined the antitumor efficacy and overall survival. As per findings, the RP2D of veliparib was 80 mg by mouth twice daily on days 1 to 12 in combination with cisplatin and gemcitabine; the DLT was myelosuppression. In BRCA⁺ pancreatic ductal adenocarcinoma, substantial antitumor activity was observed.